Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third leading cause of cancer-related deaths.Patient derived xenografts (PDX),generated by direct engraftment of tumor samples from the patients into immunocompromised mice can be used as an in vivo platform that provides the opportunity to test personalized medicine strategies.